Evidence map›Paper›PMID 32822118›Full record

ArticleCancer medicine2020

Continued smoking in African American cancer survivors: The Detroit Research on Cancer Survivors Cohort.

Carly M Malburg, Juliana Fucinari, Julie J Ruterbusch, David M Ledgerwood, Jennifer L Beebe-Dimmer, Ann G Schwartz, Michele L Cote

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Carly M MalburgDepartment of Oncology, Wayne State University School of Medicine, Detroit, MI, USA.ORCID 0000-0001-6766-1389
Juliana FucinariDepartment of Oncology, Wayne State University School of Medicine, Detroit, MI, USA.
Julie J RuterbuschDepartment of Oncology, Wayne State University School of Medicine, Detroit, MI, USA.
David M LedgerwoodDepartment of Psychiatry and Behavioral Neurosciences, Substance Abuse Research Division, Wayne State University School of Medicine, Detroit, MI, USA.
Jennifer L Beebe-DimmerDepartment of Oncology, Wayne State University School of Medicine, Detroit, MI, USA.ORCID 0000-0002-4320-739X
Ann G SchwartzDepartment of Oncology, Wayne State University School of Medicine, Detroit, MI, USA.
Michele L CoteDepartment of Oncology, Wayne State University School of Medicine, Detroit, MI, USA.ORCID 0000-0003-0312-1601
Wayne State University · US

Funding

Tumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI PAUL M STEMMER · 1985 to 2026
$68.4M
The impact of the COVID-19 pandemic on African American cancer survivors and their caregiversU01CA199240 · NCI · WAYNE STATE UNIVERSITY · PI Jennifer L Beebe-Dimmer, Ann G. Schwartz · 2017 to 2026
$15.2M
NCI NIH HHS P30 CA022453NCI NIH HHS U01 CA199240
6 · The paper itself

Abstract

Tobacco cessation among those recently diagnosed with cancer is important to improve their prognosis, yet, many cancer survivors continue to smoke. The epidemiology of tobacco use differs by race and ethnicity, and limited cessation research has been conducted in African American (AA) populations. Here, we assess demographic and clinical variables associated with continued smoking in AAs after a cancer diagnosis. The Detroit Research on Cancer Survivors study is a cohort comprised of AA cancer survivors with breast, prostate, lung, and colorectal cancers. Detroit Research on Cancer Survivors data were utilized from survivors who completed their baseline survey within 18 months of cancer diagnosis (n = 1145); 18% (n = 356) reported smoking at the time of cancer diagnosis, and 57% of these (n = 203) continued to smoke after their diagnosis. Logistic regression models were used to assess factors associated with continued smoking. Living with a smoker (odds ratio [OR] = 2.78, 95% confidence interval [CI]: 1.64, 4.70), higher cumulative years of smoking (OR = 1.03, 95% CI: 1.01, 1.05, for each year), and a prostate cancer diagnosis (OR = 7.35, 95% CI: 3.89, 13.89) were all associated with increased odds of continued smoking. Survivors with higher social well-being scores (measured by the Functional Assessment of Cancer Therapy, a quality of life assessment) were more likely to quit smoking after diagnosis (OR = 0.96, 95% CI: 0.93, 1.00). These findings highlight the continued need for personalized cessation strategies to be incorporated into treatment plans for cancer survivors.

Indexed as

AdolescentAdultAgedAged, 80 and overBlack or African AmericanCancer SurvivorsFemaleHumansMaleMichiganMiddle AgedNeoplasmsPublic Health SurveillanceQuality of LifeRisk FactorsSEER Programbreast cancercancer survivorshipcolon cancerhealth disparitieslung cancerprostate cancersmoking cessation

Identifiers

PMID32822118
PMCPMC7571811
OpenAlexW3080432217

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.